Bronchiectasis, a progressive chronic airway disease, is characterized by microbial colonization
and infection. We present an approach to the multi-biome that integrates bacterial, viral …

Background Bronchiectasis is predominantly a neutrophilic inflammatory disease. There are
no established therapies that directly target neutrophilic inflammation because little is …

Rationale: Bronchiectasis is classically considered a neutrophilic disorder, but eosinophilic
subtypes have recently been described. Objectives: To use multiple datasets available …

Background The sputum microbiome has a potential role in disease phenotyping and risk
stratification in chronic obstructive pulmonary disease (COPD), but few large longitudinal …

Background Infection is a key component of bronchiectasis pathophysiology. Characterisation
of the microbiome offers a higher degree of sensitivity and resolution than does traditional …

Neutrophilic inflammation has a key role in the pathophysiology of multiple chronic lung
diseases. The formation of neutrophil extracellular traps (NETs) has emerged as a key …

Neisseria species are frequently identified in the bronchiectasis microbiome, but they are
regarded as respiratory commensals. Using a combination of human cohorts, next-generation …

Understanding the composition and clinical importance of the fungal mycobiome was recently
identified as a key topic in a “research priorities” consensus statement for bronchiectasis. …

Introduction The chronic obstructive pulmonary disease (COPD) bacteriome associates with
disease severity, exacerbations and mortality. While COPD patients are susceptible to …

Rationale: The principal underlying inhaled antibiotic treatment in bronchiectasis is that
airway bacterial load drives inflammation, and therefore antibiotic treatment will reduce …